What are you looking for today?

Zhen, Tao, Wu, Chuan-Feng, Liu, Ping, Wu, Hai-Yan, Zhou, Guang-Biao, Lu, Ying, Liu, Jian-Xiang, Liang, Yang, Li, Keqin Kathy, Wang, Yue-Ying, Xie, Yin-Yin, He, Miao-Miao, Cao, Huang-Ming, Zhang, Wei-Na, Chen, Li-Min, Petrie, Kevin, Chen, Sai-Juan and Chen, Zhu (2012) Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Science translational medicine, 4 (127). 127ra38. ISSN 1946-6242

Document

  • [thumbnail of 2012 Targeting of AML1-ETO in t(8-21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein accepted version.pdf]
    2012 Targeting of AML1-ETO in t(8-21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein accepted version.pdf - Accepted Version
  • [thumbnail of 2012 Targeting of AML1-ETO in t(8-21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein S1.pdf]
    2012 Targeting of AML1-ETO in t(8-21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein S1.pdf - Supplemental Material

Abstract

Abstract

Nearly 60% of acute myeloid leukemia (AML) patients with the t(8;21)(q22;q22) translocation fail to achieve long-term disease-free survival. Our previous studies demonstrated that oridonin selectively induces apoptosis of t(8;21) leukemia cells and causes cleavage of AML1-ETO oncoprotein resulting from t(8;21), but the underlying mechanisms remain unclear. We show that oridonin interacted with glutathione and thioredoxin/thioredoxin reductase to increase intracellular reactive oxygen species, which in turn activated caspase-3 in t(8;21) cells. Moreover, oridonin bound AML1-ETO, directing the enzymatic cleavage at aspartic acid 188 via caspase-3 to generate a truncated AML1-ETO (ΔAML1-ETO) and preventing the protein from further proteolysis. ΔAML1-ETO interacted with AML1-ETO and interfered with the trans-regulatory functions of remaining AML1-ETO oncoprotein, thus acting as a tumor suppressor that mediates the anti-leukemia effect of oridonin. Furthermore, oridonin inhibited the activity of c-Kit(+) leukemia-initiating cells. Therefore, oridonin is a potential lead compound for molecular target-based therapy of leukemia.

Item Type: Article
Depositing User: Kevin Petrie
URI: https://sure.sunderland.ac.uk/id/eprint/12435

Further Details

More Information

Depositing User

Identifiers

Item ID
12435
Identification Number
ISSN
1946-6242

Users with ORCIDS

ORCID for Kevin Petrie

Catalogue record

Date Deposited
18 Aug 2020 18:02
Last Modified
04 Jun 2025 16:18

Contributors

Author
Tao Zhen
Author
Chuan-Feng Wu
Author
Ping Liu
Author
Hai-Yan Wu
Author
Guang-Biao Zhou
Author
Ying Lu
Author
Jian-Xiang Liu
Author
Yang Liang
Author
Keqin Kathy Li
Author
Yue-Ying Wang
Author
Yin-Yin Xie
Author
Miao-Miao He
Author
Huang-Ming Cao
Author
Wei-Na Zhang
Author
Li-Min Chen
Author
Sai-Juan Chen
Author
Zhu Chen

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)

Downloads per month over past year